• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Diquafosol sodium
Mango Powder
Nettles Leaf Extract
lutein
Bamboo Leaf Extract
TZ-SN01 Prefilled Single-nozzle Nasal Spray Device

MSN group gets US FDA nod for dimethyl fumarate capsules

expresspharmaOctober 10, 2020

Tag: MSN , FDA , dimethyl fumarate capsules , ANDA

MSN Group (MSN), receives ANDA approval for dimethyl fumarate delayed release capsule. The company manufactures active pharmaceutical ingredient (API) as well as the finished formulation of dimethyl fumarate delayed-release capsules in-house.

MSN has entered into a commercial partnership with Dr Reddy’s for marketing the product in the United States.

The medicine will be available in strengths of 120 mg and 240 mg capsules in bottle count sizes of 14 and 60 capsules, respectively.

Dimethyl fumarate is a prescription medicine used to treat relapsing forms of multiple sclerosis in adults.
Currently, the company has over 100 ANDAs and 710 DMFs.

Previous:FDA issues guidance on emergency use authorisation for COVID-19 vaccines

Next:China’s experimental COVID-19 vaccine appears safe: study

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

MSN group gets US FDA nod for dimethyl fumarate capsules | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

pharmaceutical Carbetocin Acetate(GMP standard product) Peptide

pharmaceutical Carbetocin Acetate(GMP standard product) Peptide
Bleomycin sulfate (FDA)

Bleomycin sulfate (FDA)
Professional Customized Non-Standard Rubber O-Ring

Professional Customized Non-Standard Rubber O-Ring
SUNDI -40℃ ～ 200℃ Standard One operating two systems

SUNDI -40℃ ～ 200℃ Standard One operating two systems
LGJ-30FD Standard Type Experimental Freeze Dryer

LGJ-30FD Standard Type Experimental Freeze Dryer
Marya GMP Standard Electronic Pharmaceutical Cleanroom Cargo Air Shower with High Efficiency System

Marya GMP Standard Electronic Pharmaceutical Cleanroom Cargo Air Shower with High Efficiency System
High-standard and safety Influenza Vaccine (Split virion), inactivated

High-standard and safety Influenza Vaccine (Split virion), inactivated
General Purpose Grade Expandable Polystyrene

General Purpose Grade Expandable Polystyrene
Sirolimus (FDA)

Sirolimus (FDA)
high standard and high quality Human Prothrombin Complex by Hualan biological

high standard and high quality Human Prothrombin Complex by Hualan biological

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service